New diabetes drug launched in India by US pharma Eli Lilly
Advertisement
India to enhance its diabetes medication portfolio with the launch of US pharma major Eli Lilly’s new drug in the market by end of 2015
US pharma major Eli Lilly is slated to enhance its drug portfolio in India with the launch of a new medication to treat diabetes. After having received the approval from the concerned regulatory authorities in India, the said drug will be launched by the end of this year.
In line with its plans to expand its product portfolio in India, Eli Lilly has also set its target to enhance treatment for oncology in India. A new medication in this health branch is also ready to be introduced in the Indian market by end of 2016 or early 2017.
"We are planning to introduce a new medication later this year in diabetes. We have received approvals for the same," Eli Lilly and Company India Pvt Ltd Managing Director Edgard A Olaizola told PTI.
For Eli Lilly in India, diabetes is the primary segment for the company with "around 60 to 70 per cent of our revenues in India coming from diabetes followed by oncology and the osteoporosis," Olaizola said.
The company sells a range of medicines and drug delivery devices in the diabetes segment. Last year, it had introduced Savvio, an insulin delivery device in India.
Speaking on the sidelines of the 3rd National NCD Summit 2015 organised here, Olaizola said the company is also planning to introduce another medication in oncology that could be launched by end of 2016 or early 2017.
"It has been filed for regulatory approvals," he said.
Commenting on the significance of the Indian market for Eli Lilly, he added: "India is a very important market for the company in Asia."
The biggest market for the company globally are the US, Europe as a region and Japan, he added.
US pharma major Eli Lilly is slated to enhance its drug portfolio in India with the launch of a new medication to treat diabetes. After having received the approval from the concerned regulatory authorities in India, the said drug will be launched by the end of this year.
In line with its plans to expand its product portfolio in India, Eli Lilly has also set its target to enhance treatment for oncology in India. A new medication in this health branch is also ready to be introduced in the Indian market by end of 2016 or early 2017.
"We are planning to introduce a new medication later this year in diabetes. We have received approvals for the same," Eli Lilly and Company India Pvt Ltd Managing Director Edgard A Olaizola told PTI.
For Eli Lilly in India, diabetes is the primary segment for the company with "around 60 to 70 per cent of our revenues in India coming from diabetes followed by oncology and the osteoporosis," Olaizola said.
The company sells a range of medicines and drug delivery devices in the diabetes segment. Last year, it had introduced Savvio, an insulin delivery device in India.
Speaking on the sidelines of the 3rd National NCD Summit 2015 organised here, Olaizola said the company is also planning to introduce another medication in oncology that could be launched by end of 2016 or early 2017.
"It has been filed for regulatory approvals," he said.
Commenting on the significance of the Indian market for Eli Lilly, he added: "India is a very important market for the company in Asia."
The biggest market for the company globally are the US, Europe as a region and Japan, he added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.